Detalhe da pesquisa
1.
Optimising pyrazinamide for the treatment of tuberculosis.
Eur Respir J
; 58(1)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33542052
2.
Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
J Antimicrob Chemother
; 76(3): 582-586, 2021 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33374006
3.
Quantification of rifapentine, a potent antituberculosis drug, from dried blood spot samples using liquid chromatographic-tandem mass spectrometric analysis.
Antimicrob Agents Chemother
; 58(11): 6747-57, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25182637
4.
Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability.
Antimicrob Agents Chemother
; 58(6): 3035-42, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24614383
5.
Three months of rifapentine and isoniazid for latent tuberculosis infection.
N Engl J Med
; 365(23): 2155-66, 2011 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22150035
6.
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
Am J Respir Crit Care Med
; 184(8): 972-9, 2011 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21737585
7.
Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
Antimicrob Agents Chemother
; 54(10): 4192-200, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20660695
8.
Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis.
Tuberculosis (Edinb)
; 94(3): 187-96, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24629635